Current research status and progress in comprehensive diagnosis and treatment of pancreatic cancer in the era of targeted therapy
10.3760/cma.j.issn.0529-5815.2020.01.006
- VernacularTitle: 分子靶向时代胰腺癌综合诊治的现状与展望
- Author:
Zhengkui ZHANG
1
;
Yinmo YANG
Author Information
1. Department of Surgery, Peking University First Hospital, Beijing 100034, China
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Molecular Targeted Therapy;
Molecular subtypes
- From:
Chinese Journal of Surgery
2020;58(1):22-26
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of pancreatic cancer (PC) has continuously shown an upward trend all over the world. It remains one of the most challenging malignant tumors in clinical practice and is characterized by difficult diagnosis in early stages, low surgical resection rate and poor prognosis. Due to its significant genetic heterogeneity, there are notable individual differences in disease progression, clinical efficacy, sensitivity to chemoradiotherapy, and prognosis among PC patients. In-depth study is needed to reveal the molecular biological characteristics of different PC subtypes and their correlation with clinical manifestations and chemoradiotherapy sensitivity, which could contribute to develop corresponding targeted therapeutic strategies.It is not only the fundamental basis for the innovation of PC morphological classification to molecular subtyping, but also a prerequisite for achieving a shift in treatment mode from "standard therapeutic strategy for different diseases" to "treat the same disease with different strategies" .This article reviews several hot issues on the comprehensive diagnosis and treatment of PC in the era of targeted therapy and prospects its future development.
